Ocular Therapeutix (OCUL) Interest Expenses (2013 - 2026)

Ocular Therapeutix's Interest Expenses history runs 14 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 6.94% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $13.8 million, a 10.67% increase from a year earlier, with the FY2025 full-year figure at $292.4 million, up 29.83% from the prior year.
• Interest Expenses fell to $2.8 million in Q1 2026 per OCUL's latest filing, from $5.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $13.0 million in Q1 2024 and bottomed at -$2.6 million in Q4 2022.
• The 5-year median for Interest Expenses is $3.0 million (2025), against an average of $3.4 million.
• Across the five-year window, Interest Expenses slumped 256.31% in 2022 and surged 633.43% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$2.6 million in 2022, then soared by 422.66% to $8.5 million in 2023, then slumped by 63.34% to $3.1 million in 2024, then soared by 62.59% to $5.0 million in 2025, then slumped by 45.01% to $2.8 million in 2026.
• Per Business Quant, the three latest OCUL Interest Expenses figures stand at $2.8 million (Q1 2026), $5.0 million (Q4 2025), and $3.0 million (Q3 2025).